5 Result(s)

Article

CRAF R391W is a melanoma driver oncogene

Approximately 75% of melanomas have known driver oncogenic mutations in BRAF, NRAS, GNA11 or GNAQ, while the mutations providing constitutive oncogenic signaling in the remaining melanomas are not known. We es...

Mohammad Atefi, Bjoern Titz, Jennifer Tsoi, Earl Avramis, Allison Le… in Scientific Reports (2016)

Article

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Deborah JL Wong, Lidia Robert, Mohammad S Atefi, Amanda Lassen… in Molecular Cancer (2015)

Article

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

Approximately 20% of melanomas contain a mutation in NRAS. However no direct inhibitor of NRAS is available. One of the main signaling pathways downstream of NRAS is the MAPK pathway. In this study we investig...

Mohammad Atefi, Bjoern Titz, Earl Avramis, Charles Ng, Deborah JL Wong… in Molecular Cancer (2015)

Article

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

In melanoma, dysregulation of the MAPK pathway, usually via BRAF ^V600 or NRAS ^Q61 somatic mutations, leads to constitutive ERK signali...

Deborah JL Wong, Lidia Robert, Mohammad S Atefi, Amanda Lassen… in Molecular Cancer (2014)

Article

PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody

Molecular imaging with positron emission tomography (PET) may allow the non-invasive study of the pharmacodynamic effects of agonistic monoclonal antibodies (mAb) to 4-1BB (CD137). 4-1BB is a member of the tum...

Helena Escuin-Ordinas, Mark W Elliott… in Journal for ImmunoTherapy of Cancer (2013)